Market LIVE
Published markets; coverage varies by country
Product profile · United States

IDHIFA

 ·  Patent Litigation & Settlement History ↓

IngredientENASIDENIB MESYLATE
Application typeNDA
Application209606
Product001
Dosage formTABLET
RouteORAL
StrengthEQ 50MG BASE
Approval date2017-08-01
Marketing statusPrescription
Status event—
ApplicantBRISTOL MYERS SQUIBB
Product source

Current GenericRadar decision

Year2034
SelectionCANDIDATE
ReviewFINAL
Anchor typeTRUE_DS_PATENT
Anchor date2034-09-16
Patent anchor2034-09-16
Exclusivity anchor—
Protection date2034-09-16
First Final ANDA—
Status event—

US9732062 c1/2/4/5/6; enasidenib Markush choices/exclusions compared.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
106101252030-06-21U U-2087NYDS_EQUIVALENT
———
102942152033-01-07DP/U U-2087NYDS_EQUIVALENT
———
95121072033-01-07DS/DP/U U-2087YNTRUE_DS
———
100936542034-08-01DS/DP/U U-2087NNDP
———
97386252034-08-01DS —NNDP
———
97320622034-09-16DS —YNTRUE_DS
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (1)
TypeDateRoleBasisSource
ANNUAL_DECISION_RECHECK—ANCHOR_AND_TAILUS9732062 c1/2/4/5/6; enasidenib Markush choices/exclusions compared.Source
Decision history
CurrentYearStatusReviewAnchorJudged
Y2034CANDIDATEFINAL2034-09-162026-10-17 20:32:21
N2034CANDIDATEFINAL2034-09-162026-10-15 19:53:50
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.